Recent studies reveal novel molecular insights into Alzheimer’s disease. Research from Aarhus University identified that familial SORLA mutations impair exosome production, critical for neuronal support, linking reduced exosome release to increased AD risk. Additionally, Remynd NV presented positive Phase IIa data for REM-127, targeting septin filaments to restore calcium homeostasis and reduce pathological tau, improving cognition. Further studies explore ABCA7 lipid transporter loss-of-function variants doubling AD risk, enhancing understanding of neurodegeneration pathways and potential therapeutic targets.